FDA Approval Sought for Erdafitinib in Urothelial Carcinoma
A new drug application has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.
Source: OncLive